peresolimab
eli lilly
['rheumatoid,arthritis', 'peresolimab', 'imab ']
late breaking at #acr22 promising data from a phase 2 trial of peresolimab (pd-1) in patients with rheumatoid arthritis; primary endpoint of das28 at wk 12 was met and had a good safety profile 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders